[1] Zhang J, Qi Y P, Ma N, et al. Overexpression of epcam and CD133 correlates with poor prognosis in dual-phenotype hepatocellular carcinoma[J]. J Cancer, 2020, 11(11):3400-3406. [2] Wang Y, Wang X, Huang X, et al. Integrated genomic and transcriptomic analysis reveals key genes for predicting dual-phenotype hepatocellular carcinoma prognosis[J]. J Cancer, 2021, 12(10):2993-3010. [3] 郑巧灵, 冯昌银, 连渊娥, 等. 双表型肝细胞癌六例临床病理学分析[J]. 中华病理学杂志, 2020, 49(12):1320-1322. [4] Gu H X, Huang X S, Xu J X, et al. Diagnostic value of MRI features in dual-phenotype hepatocellular carcinoma: a preliminary study[J]. J Digit Imaging, 2023, 36(6):2554-2566. [5] Zhang L, Chen J, Lai X, et al. Dual-phenotype hepatocellular carcinoma: correlation of MRI features with other primary hepatocellular carcinoma and differential diagnosis[J]. Front Oncol, 2024, 13:1253873. [6] Ouyang X, Yan Y, Zhang S, et al. Microvascular invasion is associated with poor survival in patients with dual-phenotype hepatocellular carcinoma[J]. Am J Clin Pathol, 2024, 161(3):245-255. [7] Huang K, He Y, Liang T, et al. Analysis of clinicopathologic and imaging features of dual-phenotype hepatocellular carcinoma[J]. Sci Rep, 2024, 14(1):3314. [8] Wu Q, Yu Y X, Zhang T, et al. Preoperative diagnosis of dual-phenotype hepatocellular carcinoma using enhanced MRI radiomics models[J]. J Magn Reson Imaging, 2023, 57(4):1185-1196. [9] Tian J, Pan S, Wang Y, et al. Early alpha-fetoprotein response predicts sustained tumor response following immune checkpoint inhibitors combined with targeted therapy in liver cancer[J]. Biomedicines, 2024, 12(12):2769. [10] Mulla N, Katib Y, Almughamsi A M, et al. The impact of alpha-fetoprotein (AFP), child-turcotte-pugh (CTP) score and disease staging on the survival of hepatocellular carcinoma (HCC) patients: a retrospective cohort from single oncology center[J]. Oncol Res, 2024, 33(1):149-160. [11] Liu M T, Zhang J Y, Xu L, et al. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dualphenotype hepatocellular carcinoma[J]. Radiol Med, 2023, 128(11):1333-1346. [12] Lu X Y, Xi T, Lau W Y, et al. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J]. Ann Surg Oncol, 2011, 18(8):2210-2217. [13] Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular -cholangiocarcinoma: An update[J]. J Hepatol, 2021, 74(5):1212-1224. [14] Sciarra A, Park Y N, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma[J]. Hum Pathol, 2020, 96:48-55. [15] Meng X, Liu X. Therapeutic value of estrogen receptor α in hepatocellular carcinoma based on molecular mechanisms[J]. J Clin Transl Hepatol, 2022, 10(1):140-146. |